NovaStar Financial, the infamous subprime lender that became a poster child for naked short selling conspiracy theorists, wants to settle a securities fraud lawsuit brought against it in April of 2004.
The lawsuit alleged that the company used false and misleading statements to unload $107 million worth of stock on the public between October 29th of 2003 and April 8th of 2004. Novastar has proposed a $7.5 million settlement of the suit -- but will still have to wade through many, many other similar lawsuits that resulted from the company's aggressive accounting that it allowed it to book huge profits and pay huge dividends while making loans to people who would never be able to pay them back. The stock now trades on the Pink Sheets with a market cap of less than $3 million.
Investors were warned by a cavalcade of investigative journalists and other intelligent people, including our own Peter Cohan, of the problems that ultimately led to Novastar's demise. Instead people relied on optimistic projections from insiders and conspiracy theories about a worldwide short seller plot to destroy the company that flourished on the internet. Anyone who questioned the company's accounting was harassed and had their motives and ethics questioned. That's a pretty common theme of the housing bubble, and part of the explanation for why it inflated as much as it did: People were afraid to speak up.
Last updated: February 13, 2012: 10:07 AM
Hot Stocks
DailyFinance Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- SanDisk volatility low into analyst day and sales outlook
- Obama budget requests increase in Pell Grants, Inside Higher Education says
- Stoneridge sees 2012 EPS $1.10-$1.30 vs. consensus $1.13
- Stoneridge Q2 results include $1.72/sh in gains
- Stoneridge reports Q4 diluted EPS $1.56 vs. consensus 22c
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

